ZURA news

Zura Bio announced Q3 financial results and confirmed key trial milestones. With $187.7 million in cash, the company expects to fund operations through 2028 as it awaits topline data for its TibuSHIELD and TibuSURE studies.

Zura Bio released its Corporate Overview on August 2026, disclosing it contains 'forward-looking statements' regarding its clinical development and financial future. The filing is structured solely with a disclaimer and risks.

Zura Bio Ltd filed a corporate overview for July 2026 outlining business plans. This document includes standard SEC regulatory disclaimers regarding future performance and operational risks.

Zura Bio Limited filed an amended version of its 2023 Equity Incentive Plan, outlining the framework for granting share-based compensation to employees, officers, directors and service providers. The plan amendment reflects updates to the company's compensation structure and incentive mechanisms.